TITLE

News @ a glance

AUTHOR(S)
Birnbaum, Elisa; Sibbald, Barbara; Eggertson, Laura
PUB. DATE
February 2005
SOURCE
CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p321
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents news briefs on the health care industry in Canada as of January 2005. Risk of injecting anesthetic through a tattoo according to researchers and the American Association of Nurse Anesthetists; Projected increase in health care spending in Canada in 2004; Creation of a clinical trial register by Eli Lilly and Co. that will post results from all clinical trials of marketed products.
ACCESSION #
15783997

 

Related Articles

  • Update.  // Medical Marketing & Media;Jun2004, Vol. 39 Issue 6, p9 

    Presents news items related to medical marketing in the U.S. as of June 2004. Clinical trials of weight loss drugs from Eli Lilly & Co.; Appointment of Annie Callanan as executive vice president of Advanstar/Medical Economics Communications Group.

  • Guinea Pig, Interrupted. Shalo, Sibyl // Pharmaceutical Executive;Jan2001, Vol. 21 Issue 1, p85 

    Looks at the reasons for Eli Lilly's withdrawal of its antidepressant r-fluoxetin from clinical trials in October 2000. Side effects of the drug; Concerns about the drug.

  • Pharma: Clinic Roundup.  // BioWorld Today;7/12/2012, Vol. 23 Issue 134, p8 

    The article reports that Eli Lilly and Co.'s study H8Y-MC-HBBM investigating pomaglumetad methionil, also known as mGlu2/3, in patients with acute exacerbations of schizophrenia, has produced negative results.

  • Pharma: Clinic Roundup.  // BioWorld Today;8/30/2012, Vol. 23 Issue 169, p8 

    The article reports on the announcement by Eli Lilly and Co. of its decision to end ongoing trials testing of ongoing trials testing of promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia.

  • Pharma: Clinic Roundup.  // BioWorld Today;10/9/2012, Vol. 23 Issue 196, p11 

    This section offers news briefs on clinical trials including the positive results obtained by Eli Lilly and Co. from Phase III trials of solanezumab in Alzheimer's disease and the patient enrollment initiated by Grifols SA for a Phase II study of Alpha-1 HC aerosol in cystic fibrosis.

  • Pharma: Clinic Roundup.  // BioWorld Today;3/19/2013, Vol. 24 Issue 52, p8 

    The article offers news briefs related to clinical trials, including the findings of Eli Lilly and Co. that Cialis 5 milligrams once daily co-administered with finasteride improved scores on the International Prostate Symptom Score (IPSS) and the presentation of data showing the possible...

  • Fight against sepsis advances on clinical, legislative fronts. Pollina, Kristen // Drug Topics;10/7/2002, Vol. 146 Issue 19, p47 

    Lists studies underway or just completed that assess a variety of therapies for sepsis. Phase IV trial of Eli Lilly's Xigris; French study that focuses on the use of steroids among septic-shock patients; Association of antothrombin III with a better quality of life 90 days after treatment.

  • Eli Lilly plans more trials.  // Ophthalmology Times;2/1/2003, Vol. 28 Issue 3, p7 

    Reports on the plan of Eli Lilly and Co. for the additional registration trials of the ophthalmic drug ruboxistaurin in the U.S. Failure to achieve satisfactory results on disease progression; Investigation of the positive effect of ruboxistaurin.

  • Despite quintuple disappointments, Lilly still charms investors. Raven, Kathleen // Nature Medicine;Oct2012, Vol. 18 Issue 10, p1446 

    The article informs about the delivery of negative results by Eli Lilly & Co. from five phase three clinical trials on drug agents regarding blood thinners to cancer therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics